Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IMNM | CLUSTER | bearish | 5/10 | Director Isaac Barchas and CMO Robert Lechleider sold a combined $2.93M in open-market sales over a week, with Barchas a | Jul 2, 2026 |
| STTK | CLUSTER | neutral | 3/10 | Two Shattuck Labs executives, the Chief Medical Officer and Chief Technical Officer, sold a combined $376K of stock in a | Jul 2, 2026 |
| GSK | COURT-RULING | neutral | 3/10 | In the long-running Lamictal reverse-payment antitrust case, the District Court for the District of New Jersey vacated a | Jul 2, 2026 |
| KYMR | CLUSTER | bearish | 6/10 | Kymera Therapeutics (KYMR) saw a massive insider selling cluster over the past week, with total open-market sales exceed | Jul 2, 2026 |
| SLGL | INSIDER-BUY | neutral | 2/10 | Opaleye Management Inc., a 10% owner of Sol-Gel Technologies, purchased $123K of SLGL shares on the open market over two | Jul 2, 2026 |
| ROIV | CLUSTER | neutral | 5/10 | A cluster of six Roivant insiders, including the President & CIO and the President of Immunovant, sold approximately $13 | Jul 2, 2026 |
| SEPN | CLUSTER | neutral | 2/10 | Two Septerna insiders (SVP Drug Discovery and Chief People Officer) sold a combined $148K in open-market shares after ex | Jul 2, 2026 |
| NRIX | CLUSTER | neutral | 3/10 | Nurix Therapeutics chief legal and scientific officers sold $688K in stock, including a single-day CLO sale of $581K. Th | Jul 2, 2026 |
| XERS | 3 | neutral | 3/10 | Dr. Nerissa Kreher has been appointed as a director of Xeris Biopharma Holdings, Inc., effective July 1, 2026, and filed | Jul 2, 2026 |
| AKTX | S-3 | bearish | 6/10 | Akari Therapeutics filed an S-3 registration statement to register the resale of up to 5,999,999 ADSs (representing ~480 | Jul 2, 2026 |
| CYTK | CLUSTER | neutral | 3/10 | Two C-suite executives (CFO and CCO) sold a combined $1.38M in open-market shares following option exercises, with the C | Jul 2, 2026 |
| LFCR | 8-K | bearish | 7/10 | Lifecore Biomedical disclosed that holders of all 49,263 outstanding Series A Redeemable Convertible Preferred shares ha | Jul 2, 2026 |
| VXRT | DEFA14A | bullish | 5/10 | Vaxart has reached an agreement with a group of shareholders to resolve its ongoing proxy contest, as announced via DEFA | Jul 2, 2026 |
| NTHI | 8-K | neutral | 3/10 | Dr. Ming-Fu (Alan) Chiang resigned from the board and scientific advisory board effective June 27, 2026, with no disagre | Jul 2, 2026 |
| ABT | COURT-RULING | neutral | 3/10 | A New Jersey federal district court granted Abbott Laboratories' motion to dismiss a product liability lawsuit concernin | Jul 2, 2026 |
| AAWH | COURT-RULING | neutral | 2/10 | The court denied plaintiff Minchin's motion to disqualify the union's counsel in his employment lawsuit against Ascend W | Jul 2, 2026 |
| ADCT | 8-K | neutral | 2/10 | ADC Therapeutics granted one-time retention awards to its CEO, CFO, and CMO totaling approximately $2.9M in cash and 1.0 | Jul 2, 2026 |
| IQV | COURT-RULING | bullish | 6/10 | IQVIA won denial of plaintiff's renewed motion for class certification in a TCPA fax-advertisement class action. The cou | Jul 2, 2026 |
| IOVA | 8-K | neutral | 2/10 | Iovance Biotherapeutics filed an 8-K to update its corporate presentation, which is a routine administrative event. The | Jul 2, 2026 |
| ARDX | 8-K | neutral | 4/10 | Ardelyx drew down $50 million under its existing Term F Loan facility with SLR Investment Corp. on June 29, 2026. The lo | Jul 2, 2026 |
| LENZ | 8-K | neutral | 2/10 | Director Zach Scheiner resigned from the LENZ Therapeutics board effective June 30, 2026, with no dispute or disagreemen | Jul 2, 2026 |
| ORMP | CLUSTER | neutral | 4/10 | COO/CBO Joshua Hexter and CFO Avraham Gabay collectively sold $942K in open-market shares on July 1, 2026, representing | Jul 2, 2026 |
| QCLS | 8-K | neutral | 4/10 | Q/C Technologies terminated its crypto-mining license agreement with LightSolver and is pivoting entirely to an optical | Jul 2, 2026 |
| EDSA | S-3 | neutral | 3/10 | Edesa Biotech filed an S-3 registration statement to register 729,241 common shares for resale by selling shareholders w | Jul 2, 2026 |
| PHGE | 8-K | bearish | 6/10 | BiomX Inc. (PHGE, $4M market cap) dismissed PwC and engaged Barzily & Co. as its new auditor, effective July 1, 2026. Pw | Jul 2, 2026 |
| QURE | CLUSTER | mixed | 5/10 | uniQure's CEO and CMO sold ~$2.9M in open-market sales within days of a $225M public offering. The sales are modest rela | Jul 2, 2026 |
| MTVA | 424B5 | bearish | 6/10 | MetaVia Inc. filed a 424B5 prospectus supplement to increase its ATM offering capacity from $2.3M to $4.0M. The company | Jul 2, 2026 |
| RPRX | CLUSTER | neutral | 2/10 | Two EVPs at Royalty Pharma sold a combined $6.01M in open-market sales over a one-week window, representing just 0.02% o | Jul 2, 2026 |
| TNYA | 8-K | neutral | 4/10 | Tenaya Therapeutics terminated its lease for the former Genetic Medicines Manufacturing Center in Union City, CA, which | Jul 2, 2026 |
| PYXS | 8-K | mixed | 6/10 | Pyxis Oncology entered into a securities purchase agreement for a $50 million private placement (plus up to $64 million | Jul 2, 2026 |